Review of the clinical evidence for interferon β 1a (Rebif®) in the treatment of multiple sclerosis
Authors:
Open Access
- 1 April 2008
- journal article
- review article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 4 (2) , 321-336
Abstract
Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articlesor submit your research for publishingKeywords
This publication has 91 references indexed in Scilit:
- Treatment of early-onset multiple sclerosis with intramuscular interferonβ-1a: long-term resultsNeurological Sciences, 2007
- Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI ProjectNeurological Sciences, 2006
- Secondary progressive multiple sclerosis: current knowledge and future challengesThe Lancet Neurology, 2006
- The IFNβ treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, ItalyNeurological Sciences, 2005
- Subcutaneous Recombinant Interferon-??-1a (Rebif??)Drugs, 2005
- Thyroid autoimmunity and dysfunction associated with type I interferon therapyClinical and Experimental Medicine, 2004
- Haematological Effects of Interferon-??-1a (Rebif??) Therapy in Multiple SclerosisDrug Safety, 2004
- Hepatic Reactions During Treatment of Multiple Sclerosis with Interferon-??-1aDrug Safety, 2003
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983